MedTrace Logo

Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

NCT07168993 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2063

Last updated 2026-03-18

No results posted yet for this study

Summary

Evaluate FlowPath Lung Diagnostic Test of Sputum Samples to Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, \>6 to \<30 mm in Diameter, Determined by LDCT.

Conditions

  • Lung Cancer (Diagnosis)

Interventions

OTHER

Standard medical treatment

Standard of care follow up per institution

OTHER

Standard medical treatment

SOC per institution

Sponsors & Collaborators

  • bioAffinity Technologies Inc.

    lead INDUSTRY

Principal Investigators

  • Maria Zannes · bioAffinity Technologies Inc.

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-25
Primary Completion
2029-04-01
Completion
2029-07-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07168993 on ClinicalTrials.gov